American Society of Interventional Pain Physicians

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Island Ambulatory Surgery Center in Brooklyn, New York

Retrieved on: 
Thursday, November 9, 2023
Insurance, Standard of care, Urology, NYSE, Spine, Epidural steroid injection, Elective surgery, Physician, American Society of Interventional Pain Physicians, MD, American Board of Commissioners for Foreign Missions, Injection, MBA, Society, MSHS, Podiatry, MLSS, Mount Sinai Health System, Hospital, ESI, Safety, Pain management, American Board of Anesthesiology, Nursing, Anesthesiology

ROSELAND, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into Island Ambulatory Surgery Center, a multi-specialty ambulatory surgery center based in Brooklyn, New York with a focus on pain management, orthopedics and spine care, urology, podiatry and plastic surgery. Island Ambulatory Surgery Center is affiliated with Mount Sinai Health System (MSHS), which operates 19 hospitals across New York.

Key Points: 
  • Island Ambulatory Surgery Center is affiliated with Mount Sinai Health System (MSHS), which operates 19 hospitals across New York.
  • Sales to Island Ambulatory Surgery Center represent the Company’s first foray into the ambulatory surgery center market—an addressable market of more than 9,000 centers across the U.S.
  • Dr. Leon Reyfman was one of a team of four doctors who completed eighteen cases using the CompuFlo Epidural system at Island Ambulatory Surgery Center, in which they reported 100% success.
  • Based on the favorable response to our technology, we remain confident that the CompuFlo Epidural system will ultimately become the standard of care in epidural analgesia.”

Relievant Medsystems Introduces Intracept Simulator System Powered by Medability for Improved and Expanded Physician Training Opportunities

Retrieved on: 
Thursday, September 21, 2023
Learning, Partnership, Education, Brain, American Society of Interventional Pain Physicians, Pain management, MD, Patient, Physician, BVN, Annual general meeting, Diagnosis, Medical imaging, Nursing

CHICAGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IPSIS Annual Meeting -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced the release of the Intracept® Simulator System, an advanced training platform for the Intracept® Procedure.

Key Points: 
  • CHICAGO, Sept. 21, 2023 (GLOBE NEWSWIRE) -- IPSIS Annual Meeting -- Relievant Medsystems , a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, today announced the release of the Intracept® Simulator System, an advanced training platform for the Intracept® Procedure.
  • The Intracept Simulator System is based on Medability’s SimBone™ simulation platform, using radiation-free simulation technology to provide an immersive hands-on training experience, including virtual x-ray, computed tomography (CT) imaging, and navigation with a realistic lumbosacral spine model.
  • The system allows a consistent and reliable learning experience using next-generation Intracept® Access Instruments and expands training opportunities for physicians.
  • “The Intracept Simulator System is an important innovation that will empower more physicians to provide their patients with vertebrogenic pain relief.”
    The Intracept Procedure is a minimally invasive, long-lasting treatment for individuals suffering from chronic vertebrogenic low back pain.

JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference

Retrieved on: 
Thursday, August 31, 2023
Pain, Patent, Diabetic neuropathy, Janon, American Society of Interventional Pain Physicians, United States patent law, Chronic pain, Patient, Conference, Ohio Society of New York, Pharmaceutical industry

LAS VEGAS, Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25th Annual Global Investment Conference in New York City. JanOne's Chief Medical Officer, Dr. Amol Soin, will appear via recorded video and attend the conference in person to represent the company's mission and progress.

Key Points: 
  • LAS VEGAS, Aug. 31, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, will participate in investor sessions at the H.C. Wainwright 25th Annual Global Investment Conference in New York City.
  • JanOne's Chief Medical Officer, Dr. Amol Soin, will appear via recorded video and attend the conference in person to represent the company's mission and progress.
  • Dr. Soin's virtual presentation will be shown September 11 — 13th and will be accessible on the JanOne.com website in subsequent days.
  • This week, on August 29, JanOne announced that it had received a US Patent for its use of its novel formulation of low-dose naltrexone, Jan123, to treat chronic pain.

JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting

Retrieved on: 
Friday, August 25, 2023
II, LAS, Pain, Ohio Society of New York, Diabetic neuropathy, Janon, Research, Patient, Physician, American Society of Interventional Pain Physicians, Consumer electronics, Pharmaceutical industry

LAS VEGAS, Aug. 25, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the biopharmaceutical company focused on developing non-addicting painkillers and novel treatments for the causes of pain, has won a prestigious "Best Abstract" award for reporting that JanOne's treatment for diabetic neuropathy showed both effectiveness against pain and potential to improve nerve function.

Key Points: 
  • Abstract explained Jan101's statistically significant reduction in pain and improvement in nerve conduction velocity in prior Phase II study.
  • The abstract was presented at the annual meeting of the Ohio Society of Interventional Pain Physicians (OHSIPP), one of the nation's largest regional pain management meetings typically attracting 300 physicians from around the country.
  • The JanOne abstract, selected as one of the top three, analyzed prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.
  • "Winning this award is a gratifying validation by independent peers of the work we are doing," Dr. Soin said.

JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting

Retrieved on: 
Friday, August 18, 2023
Diabetic neuropathy, Extremities, Ohio Society of New York, JAN, Risk, Physician, PAD, Hypoesthesia, CRPS, American Society of Interventional Pain Physicians, LAS, Patient, Security (finance), FDA, Pharmaceutical industry, Pain, Janon

LAS VEGAS, Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.

Key Points: 
  • JAN101 Showed Statistically Significant Reduction in Pain and Improvement in Nerve Conduction Velocity in Prior Phase II study.
  • LAS VEGAS, Aug. 18, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, will present prior data on Jan101's randomized double blind placebo-controlled trial in diabetic neuropathy patients.
  • The Ohio Society of Interventional Pain Physicians annual meeting is a large regional pain management meeting from August 17 – 20th that draws attendance from physicians across the US.
  • Diabetic neuropathy is an often-debilitating condition that is on the rise in the USA characterized by burning pain and numbness typically in the extremities.

Hoag Welcomes Renowned Specialist to lead Pain Management Program

Retrieved on: 
Wednesday, August 16, 2023
Diabetic neuropathy, American Academy of Physical Medicine and Rehabilitation, University, Education, Anesthesiology, Diabetes, American Board of Physical Medicine and Rehabilitation, Neuralgia, North American Spine Society, Ageing, Quality of life, Spine, American Society of Interventional Pain Physicians, American Academy, Peripheral neuropathy, Pain, Pain management, American Board of Commissioners for Foreign Missions, Ron, Rehabilitation, Patient, Chronic pain, Accreditation, Accreditation Council, American Board of Anesthesiology, Physical medicine and rehabilitation, Curriculum, Medicine, Nursing, Dentistry

NEWPORT BEACH, Calif., Aug. 16, 2023 /PRNewswire/ -- Hoag is advancing the care and management of pain patients in Orange County with the addition of Charles De Mesa, D.O, M.P.H., who will serve as Chief of Interventional Pain, Physical Medicine & Rehabilitation at the Hoag Spine Center.

Key Points: 
  • He joins the multidisciplinary, specialized team of spine care experts at Hoag to lead and develop the outpatient interventional pain management and rehabilitation services.
  • "His role will expand Hoag's commitment to comprehensive management and continuity of care for patients contending with pain."
  • Dr. De Mesa comes to Hoag from the University of California, Davis, Department of Anesthesiology and Pain Medicine, where he served as the principal investigator in multiple pain management trials.
  • "Pain management is a critical component of what we do at the Hoag Spine Center," said Adam Kanter, M.D., associate executive medical director of the Pickup Family Neurosciences Institute.

Nalu Medical, Inc. Announces First Enrollment of COMFORT-2 Peripheral Nerve Stimulation Randomized Controlled Trial

Retrieved on: 
Wednesday, May 31, 2023
Technology, Medical Devices, Surgery, Neurology, Clinical Trials, Nanotechnology, Biotechnology, Physical Therapy, General Health, Health, Ankle, Medicine, Diabetic neuropathy, Additive effect, Shoulder, SCS, American Society of Interventional Pain Physicians, Clinical trial, Trial of the century, Foot, Spinal cord, Nalu, Brain, PNS, Pain, Patient, Clinical study design, Randomized controlled trial, Neuropathic pain, Nerve, Pain management, Spinal cord stimulator, FDA, Chronic pain, Safety, Society, Treatment, Knee, Level 1, Medical device, Nursing, Medical imaging, Pharmaceutical industry, Neuroscience

Nalu Medical, Inc. (“Nalu”) a Carlsbad, California-based company that markets a minimally invasive neurostimulation implant for the management of chronic intractable pain for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, announces the first patient enrollment in the Clinical Study Of A Micro-Implantable Pulse Generator For the Treatment of Peripheral Neuropathic Pain (COMFORT-2) Peripheral Nerve Stimulation Randomized Controlled Trial.

Key Points: 
  • Nalu Medical, Inc. (“Nalu”) a Carlsbad, California-based company that markets a minimally invasive neurostimulation implant for the management of chronic intractable pain for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, announces the first patient enrollment in the Clinical Study Of A Micro-Implantable Pulse Generator For the Treatment of Peripheral Neuropathic Pain (COMFORT-2) Peripheral Nerve Stimulation Randomized Controlled Trial.
  • The Nalu PNS system incorporates a battery-free, micro implantable pulse generator (micro-IPG™), powered by an externally worn device (Therapy Disc) housing the battery and controller.
  • Dr. John Hatheway, interventional pain physician at Northwest Pain Care in Spokane, Washington, enrolled the first patient in the COMFORT-2 randomized controlled trial.
  • We are committed to being the leader in PNS clinical data development.”
    This is the second PNS randomized controlled trial sponsored by Nalu Medical.

South Carolina is the First state in 2023 to be “SUNucated”

Retrieved on: 
Wednesday, May 17, 2023
Life, Curriculum, Skin cancer, Dermatology, School, Personal protective equipment, Student, American Society of Interventional Pain Physicians, Federal Food, Drug, and Cosmetic Act, MD, Risk, Weather, FRCPC, Society, Legislation, Nursing

The law, signed by Governor Henry McMaster, also enables children to wear protective clothing and allows schools to teach students sun safety curriculum.

Key Points: 
  • The law, signed by Governor Henry McMaster, also enables children to wear protective clothing and allows schools to teach students sun safety curriculum.
  • South Carolina is the 27th state to adopt model legislation that is the foundation of the SUNucate initiative developed by the American Society for Dematologic Surgery Association (ASDSA) to address barriers to sunscreen use in school and camps and promotes sun-safe behaviors.
  • “I congratulate South Carolina on passing this critical common-sense legislation to instill sun-safe habits and protect children from overexposure to the sun,” said ASDSA President Vince Bertucci, MD, FRCPC.
  • Sunscreens are regulated as over-the-counter drugs under the Federal Food, Drug and Cosmetic Act, making them subject to these bans.

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within The Pain and Rehabilitation Medical Group in Torrance, California

Retrieved on: 
Tuesday, May 16, 2023
Epidural steroid injection, Injection, American Society of Interventional Pain Physicians, University, American Board of Anesthesiology, Intervention, MLSS, North American Neuromodulation Society, Spine, University of Washington School of Medicine, Regenerative medicine, American Medical Association, Organization, American Board of Commissioners for Foreign Missions, Rehabilitation, Hospital, Pain management, Santa Clara University, Medical director, Ronald Reagan UCLA Medical Center, Harbor–UCLA Medical Center, ESI, NYSE, Safety, North American Spine Society, Dentistry, Anesthesiology, Pain

ROSELAND, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery systems that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables into The Pain and Rehabilitation Medical Group in Torrance, California.

Key Points: 
  • ROSELAND, N.J., May 16, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery systems that provide painless and precise injections, today announced that it has commenced sales of CompuFlo ® Epidural disposables into The Pain and Rehabilitation Medical Group in Torrance, California.
  • Dr. Proano initially conducted eight cases using the CompuFlo Epidural system, in which he reported 100% success.
  • The evaluation included Epidural Steroid Injection (ESI) procedures within the lumbar, thoracic and cervical thoracic junction of the spine.
  • Dr. Proano also completed an advanced specialty fellowship in Interventional and Multidisciplinary Pain Management at UCLA Medical Center.

Field-Leading Expert on Post Traumatic Stress Awarded Outstanding Achievement by American Society of Interventional Pain Physicians

Retrieved on: 
Tuesday, April 4, 2023
STELLA, Psychology, Trauma center, Depression, Post, Traumatic brain injury, American Society of Interventional Pain Physicians, Anxiety, SOF, Special forces, Post-traumatic stress disorder, SGB, Multimedia, TBI, Stella, Physician, Biology, Suicidal ideation, Trauma, Society, Injury, PTSD, Meat, Nursing, Pharmaceutical industry, Ketamine, Research

CHICAGO, April 4, 2023 /PRNewswire/ -- Stella, a leader in treatment of Post Traumatic Stress Disorder (PTSD) & Traumatic Brain Injury (TBI) announces today that its Chief Medical Officer, Dr. Eugene Lipov, has been awarded Outstanding Achievement in Research by the American Society of Interventional Pain Physicians (ASIPP).

Key Points: 
  • CHICAGO, April 4, 2023 /PRNewswire/ -- Stella, a leader in treatment of Post Traumatic Stress Disorder (PTSD) & Traumatic Brain Injury (TBI) announces today that its Chief Medical Officer, Dr. Eugene Lipov, has been awarded Outstanding Achievement in Research by the American Society of Interventional Pain Physicians (ASIPP).
  • Dr. Lipov was awarded with the honor after introducing the groundbreaking "Special Operations Force (SOF) Protocol" at the annual ASIPP conference .
  • This biological treatment was developed specifically to treat the Special Forces cohort for TBI and PTSD.
  • "PTSD and TBI in our special operations forces is no longer a life sentence," explains Dr. Lipov.